RareCyte, a Seattle, WA-based Life Sciences company providing precision biology platforms including instruments, reagents, software, and services, raised $20M in funding.
The round was led by Forest Road, Arboretum Ventures and F-Prime Capital and investors HealthQuest Capital, 5AM Ventures, Agilent Technologies, Company founder Ron Seubert, Sheatree capital, and GKCC LLC.
The company intends to use the funds to drive an expansion of the orion spatial biology platform including commercializing new multiplex assays, reagent products, and software applications. The funding is also expected to support expansion of RareCyte’s Precision Biology Services including spatial biology and liquid biopsy assays utilizing its Seattle, WA-based labs and scientific personnel performed under CLIA and ISO 13485 certifications.
Led by Joe Victor, President and CEO, RareCyte is a precision biology company that designs, manufactures, and markets worldwide end-to-end integrated platforms enabling advances in discovery, translational and future clinical markets. The RareCyte Orion platform has been adopted worldwide as a spatial biology platform that addresses the translational market requirements from discovery applications to clinical trial support. Orion enables rapid sub-cellular scanning and analysis of tissue and blood samples for up to 20 biomarkers with turn-around times that will support large cohort studies. The platform includes a broad array of validated biomarkers allowing immediate access by researchers and clinicians to advance studies across immuno-oncology, immunology, neurology, infectious disease, and other critical disease areas.
FinSMEs
27/06/2024